Imatinib CAS No. 152459-95-5 Used for Antineoplastic Agents

Min.Order / FOB Price:Get Latest Price

0 Gram	Negotiable

0 Gram

Negotiable

Min.Order :0 Gram
Purity: 99%
Payment Terms : L/C

Keywords

152459-95-5 152459-95-5 152459-95-5

Quick Details

Appearance:white crystalline powder
Application:use in chemical
PackAge:bags
ProductionCapacity:12|Kilogram|Day
Storage:Kept in a well-closed, light-resistant,dry and cool place
Transportation:by sea or express

Superiority:

1. Rich experience.

Our company is a professional production leading factory in China in pharmaceutical area of many years, our products have exported to Germany, Spain, UK, USA, Australia, Middle East, and so on other country, and we have got very good feedback from our customers, we had Established long friendly relations of cooperation. High quality, best price!

2. Great quality, purity and favourable.

Good quality is one of our secret success, welcome order the samples, MOQ just 10 grams.

3. Safe and fast delivery.

We have warehouse in Australia, Canada and England, we have large amounts of stock in the warehouse, can ship to you directly from our foreign warehouse! So we can delivery quickly at the very day when receive the payment. And We offer melting powder into liquid service.

4. Good after-sales service.

Details:

Imatinib CAS No. 152459-95-5 Used for Antineoplastic Agents

Quick Details

CAS No.: 152459-95-5
Other Names: IMA-3
MF: C29H31N7O
EINECS No.: 152459-95-5
Place of Origin: Shanghai, China (Mainland)
Type: Antineoplastic Agents
Grade Standard: Medicine Grade
Usage: Animal Pharmaceuticals
Brand Name: TwoChem
Model Number: 152459-95-5
Purity: 99%
Appearance: Orange powder
Application: Pharmaceutical intermediates
Introduction

Imatinib is suitable for being applied to adult patients in acute transformation phase, accelerated phase, and chronic phase with treatment failure with interferon. CML is a kind of hematopoietic stem cell disease caused by the DNA abnormalities in the bone marrow stem cells. DNA abnormalities will produce abnormal proteins and interfere with the normal generation process of the white blood cells in the bone marrow, resulting in the sharp increase in the number of white blood cells. CML is divided into three phases including chronic phase, accelerated phase and crisis phase with the average survival period of the patients in crisis phase being only 2-3 months.

Imatinib is also effective in treating the gastrointestinal stromal tumor with the efficiency being about 50%.

View All

Visit Store